AMAG Pharmaceuticals AMAG today announced positive
preliminary data from the IDA-303 study. IDA-303 is a single arm,
open-label extension study that evaluated the safety and efficacy of
repeat dosing with ferumoxytol in patients with persistent or recurring
iron deficiency anemia (IDA) regardless of the underlying cause and a
history of unsatisfactory oral iron therapy or in whom oral iron could
not be used. Patients were eligible to enroll in the IDA-303 extension
study after they completed IDA-301, which was a double-blind,
placebo-controlled trial that randomized patients to receive either a
one gram intravenous course of ferumoxytol or placebo, the results of
which were previously reported by the company and presented at the
American Society of Hematology annual meeting in December
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in